Menu
Search
|

Menu

Close
X

Progenics Pharmaceuticals Inc PGNX.OQ (NASDAQ Stock Exchange Global Select Market)

5.97 USD
-- (--)
As of Feb 17
chart
Previous Close 5.97
Open --
Volume --
3m Avg Volume 245,582
Today’s High --
Today’s Low --
52 Week High 11.71
52 Week Low 4.61
Shares Outstanding (mil) 70.27
Market Capitalization (mil) 515.08
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
5
FY16
69
FY15
9
EPS (USD)
FY17
-0.470
FY16
0.152
FY15
-0.561
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
8.10
5.77
Price to Book (MRQ)
vs sector
6.91
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
66.48
16.52
LT Debt to Equity (MRQ)
vs sector
64.82
12.22
Return on Investment (TTM)
vs sector
-3.04
14.43
Return on Equity (TTM)
vs sector
-5.26
16.13

EXECUTIVE LEADERSHIP

Peter Crowley
Independent Chairman of the Board, Since 2010
Salary: --
Bonus: --
Mark Baker
Chief Executive Officer, Director, Since 2011
Salary: $593,551.00
Bonus: $53,224.00
Patrick Fabbio
Chief Financial Officer, Senior Vice President, Since 2015
Salary: $362,600.00
Bonus: --
Vivien Wong
Executive Vice President - Development, Since 2016
Salary: $390,152.00
Bonus: --
Jeffrey Summer
Senior Vice President - Strategy and Performance, Since 2015
Salary: $242,083.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 World Trade Ctr Fl 47
NEW YORK   NY   10007-0089

Phone: +1646.9752500

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.

SPONSORED STORIES